Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

European Journal of Nuclear Medicine

Volumn 27, Issue 7, 2000, Pages 766-777

  Wiseman, Gregory A ^a   White, Christine A ^b   Stabin, Michael ⁱ   Dunn, William L ^a   Erwin, William ^c   Dahlbom, Magnus ^d   Raubitschek, Andrew ^e   Karvelis, Kastytis ^f   Schultheiss, Timothy ^h   Witzig, Thomas E ^a   Belanger, Richard ^g   Spies, Stewart ^c   Silverman, Daniel H S ^d   Berlfein, Judy R ^b   Ding, Eric ^b   Grillo López, Antonio J ^b  

^a MAYO CLINIC   (United States)

^b BIOGEN   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g Ryan Belanger Associates   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ Department of Diagnostic Radiology ^*

Author keywords

Dosimetry; IDEC Y2B8; Non Hodgkin's lymphoma; Radioimmunotherapy; Rituximab; Yttrium 90 Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 0033922969     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590000276     Document Type: Article

References (21)

1. 1. Wilder R, DeNardo G, DeNardo S. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14: 1383-1400.
2. 2. Spar I, Bale W, Marrack D, Dewey W, McCardle R, Harper P. I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer 1967; 20: 864-870.
3. 3. Goldenberg D, DeLand F, Kim E, Bennett S, Primus F, van Nagell J Jr., Estes N, DeSimone P, Rayburn P. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-1388.
4. 4. Berger M. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971; March (Suppl 5): 5-23.
5. 5. Kocher D. Radioactive decay data tables - a handbook of decay data for application to radiation dosimetry and radiological assessments. U.S. Department of Energy, 1981.
6. 6. Kaminski M, Zasadny K, Francis I, Fenner M, Ross C, Milik A, Estes J, Tuck M, Regan D, Fisher S, Glenn S, Wahl R. Iodine-131 -anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981.
7. 7. Gansow O. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Int J Rad Appl Instrum [B] 1991; 18: 369-381.
8. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15: 1017-1025.
9. 9. Witzig T, White C, Wiseman G, Gordon L, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder R, Spies S, Silverman D, Parker E, Grillo-López A. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
10. 10. Knox S, Goris M, Trisler K, Negrin R, Davis T, Liles T-M, Grillo-López A, Chinn P, Varns C, Ning S-C, Fowler S, Deb N, Becker M, Marquez C, Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457-470.
11. 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium. AACR Annual Meeting 1999; 40: 574, #3786.
12. 12. Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
13. 111In-labelled platelets in organs. Eur J Nucl Med 1982; 7: 80-84.
14. 14. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, 1988.
15. 15. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-694.
16. 16. ICRP23. International Commission on Radiological Protection. International Commission on Radiological Protection 1975; 23.
17. 17. Metropolitan Life Foundation. Stat Bull Metrop Insur Co 1983; 64: 4.
18. 18. Siegel J, Lee R, Pawlyk D, Horowitz J, Sharkey R, Goldenberg D. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Appl Radiat Instr 1989; 16 (Part B): 553-559.
19. 19. Berinstein N, Grillo-López A, White C, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
20. 131I-hLL2) anti-CD22 MAb against B-cell malignancies. Soc Nucl Med 1998; 39: #273.
21. 21. Wiseman G, White C, Witzig T, Gordon L, Emmanouilides C, Raubitschek A, Janakiraman N, Spies S, Silverman D, Gutheil J, Schilder R, Parker E, Rosenberg J, Grillo-López A. IDEC-Y2B8 radioimmunotherapy: baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry. Blood 1998; 92 (10 Suppl): 417a, #1721.